CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Impact of tertiary lymphoid structures on prognosis and therapeutic response in pancreatic ductal adenocarcinoma.
Impact of tertiary lymphoid structures on prognosis and therapeutic response in pancreatic ductal adenocarcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
TLS 的形成对于改善 PDAC 患者的预后至关重要。未来，研究肿瘤浸润 B 细胞和 TLS 的遗传学和免疫特征可能有助于增强 PDAC 中的适应性免疫并设计个性化疗法。
胰腺导管腺癌（PDAC）已知具有异质性促结缔组织增生肿瘤微环境（TME），其中含有大量免疫抑制细胞。近年来，PDAC中高B细胞浸润作为潜在治疗靶点受到越来越多的关注。
我们的文献综述总结了肿瘤相关三级淋巴结构（TLSs）的特征，并重点介绍了探索TLSs在PDAC患者中的临床结局及其对TME直接影响的关键研究。
肿瘤内TLS的位置、密度和成熟阶段在决定预后中起关键作用，并且是癌症免疫治疗中一个新出现的靶点。
Pancreatic ductal adenocarcinoma (PDAC) is known to have a heterogeneous desmoplastic tumour microenvironment (TME) with a large number of immunosuppressive cells. Recently, high B-cell infiltration in PDAC has received growing interest as a potential therapeutic target.
Our literature review summarises the characteristics of tumour-associated tertiary lymphoid structures (TLSs) and highlight the key studies exploring the clinical outcomes of TLSs in PDAC patients and the direct effect on the TME.
The location, density and maturity stages of TLSs within tumours play a key role in determining the prognosis and is a new emerging target in cancer immunotherapy. DISCUSSION: TLS development is imperative to improve the prognosis of PDAC patients. In the future, studying the genetics and immune characteristics of tumour infiltrating B cells and TLSs may lead towards enhancing adaptive immunity in PDAC and designing personalised therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
